---
title: "Hansoh Pharma Reports Promising Phase 1 Results for Risvutatug Rezetecan in Advanced NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269211040.md"
description: "Hansoh Pharmaceutical Group Co. Ltd. announced promising phase 1 results for risvutatug rezetecan, a B7-H3-targeted ADC, in advanced NSCLC patients. The ARTEMIS-001 trial showed encouraging anti-tumor activity, especially in non-squamous NSCLC without AGAs, with a manageable safety profile. The drug has received breakthrough therapy designation in China for advanced NSCLC following progression after platinum-based chemotherapy."
datetime: "2025-12-10T09:54:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269211040.md)
  - [en](https://longbridge.com/en/news/269211040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269211040.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/269211040.md) | [繁體中文](https://longbridge.com/zh-HK/news/269211040.md)


# Hansoh Pharma Reports Promising Phase 1 Results for Risvutatug Rezetecan in Advanced NSCLC

Hansoh Pharmaceutical Group Co. Ltd. announced results from a phase 1 study of risvutatug rezetecan (HS-20093/GSK5764227), a B7-H3-targeted antibody-drug conjugate (ADC), in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC). The findings were presented in a mini oral session at ESMO Asia 2025 on December 5. The ARTEMIS-001 trial assessed the safety and efficacy of risvutatug rezetecan at doses of 8.0 mg/kg and 10.0 mg/kg every three weeks in Chinese adult patients with advanced solid tumors, including NSCLC patients who had progressed on or were intolerant to standard treatment. The drug demonstrated encouraging anti-tumor activity, particularly in patients with non-squamous NSCLC without actionable genomic alterations (AGAs). The safety profile was manageable, with hematological toxicities being the most common grade ≥3 treatment-related adverse events. No new safety signals were identified in the study. Risvutatug rezetecan has received breakthrough therapy designation in China for advanced/metastatic non-squamous NSCLC without AGAs following progression after platinum-based chemotherapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HANSOH PHARMA (03692.HK)](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh Pharmaceutical's Application for Lung Cancer Drug Accepted in China](https://longbridge.com/en/news/277426944.md)
- [Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals](https://longbridge.com/en/news/277340041.md)
- [Hansoh Pharmaceutical to Raise HK$4.68 Billion via Zero-Coupon Convertible Bonds](https://longbridge.com/en/news/273753448.md)
- [Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib](https://longbridge.com/en/news/276393466.md)
- [Targeted therapies to join chemo as oncology treatment backbone](https://longbridge.com/en/news/277929717.md)